Compliance and adherence in glaucoma management

Robin, Alan L.; Grover, Davinder S.

doi:10.4103/0301-4738.73693

Cited by 104 publications

(86 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In India, it is the leading cause of treatable non-reversible blindness. [1] Primary open angle glaucoma (POAG) is defined as a chronic optic neuropathy with characteristic changes in the optic disc and visual field. Risk factors for POAG include older age, black race, family history (first-degree relative), thinner central corneal thickness, myopia, and elevated intraocular pressure (IOP).…”

Section: Introductionmentioning

confidence: 99%

Drug use in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital

Yadav

Patel

2013

Indian J Pharmacol

View full text Add to dashboard Cite

Objective:To study drug use pattern in patients of primary open angle glaucoma (POAG) and to analyze the cost of different anti-glaucoma medications.Materials and Methods:This prospective study was carried in the glaucoma clinic of a tertiary care teaching hospital over a period of 9 months. The data collected for patients with POAG included the patient's demographic details and the drugs prescribed. Data were analyzed for drug use pattern and cost drugs used.Results:In a total 180 prescriptions (297 drugs) analyzed, most drugs (83.83%) were prescribed by topical route as eye drops. β blockers (93.88%) were found to be the most frequently prescribed for POAG. Timolol (82.22%) was the most frequently prescribed drug and timolol with acetazolamide (17.22%) was the most commonly prescribed drug combination. Fixed dose combinations constituted 26.66% of prescriptions. β blockers were found to be cheaper than other anti-glaucoma drugs while prostaglandins analogs were the costliest. Instructions about the route, frequency and duration of treatment were present in all prescriptions. However, instructions regarding instillation of eye drops were missing in all prescriptions.

show abstract

Section: Introductionmentioning

confidence: 99%

Drug use in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital

Yadav

Patel

2013

Indian J Pharmacol

View full text Add to dashboard Cite

show abstract

“…In both cases, since a key function of aqueous humor is to bathe and nourish the avascular lens, cornea, and TM, reduced aqueous humor circulation through the conventional TM outflow pathway will further exacerbate the condition of the diseased tissue [1,3,7]. In addition, therapeutic compliance remains a very serious issue with published estimates of 27.8%, 50%, or even 75% noncompliance [45][46][47][48]. This is primarily due to side effects and the requirement for daily self-application of eye drops.…”

Section: Discussionmentioning

confidence: 99%

Induced Pluripotent Stem Cells Restore Function in a Human Cell Loss Model of Open-Angle Glaucoma

DW¹,

X²

2016

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Normally, trabecular meshwork (TM) and Schlemm's canal inner wall endothelial cells within the aqueous humor outflow pathway maintain intraocular pressure within a narrow safe range. Elevation in intraocular pressure, because of the loss of homeostatic regulation by these outflow pathway cells, is the primary risk factor for vision loss due to glaucomatous optic neuropathy. A notable feature associated with glaucoma is outflow pathway cell loss. Using controlled cell loss in ex vivo perfused human outflow pathway organ culture, we developed compelling experimental evidence that this level of cell loss compromises intraocular pressure homeostatic function. This function was restored by repopulation of the model with fresh TM cells. We then differentiated induced pluripotent stem cells (iPSCs) and used them to repopulate this cell depletion model. These differentiated cells (TM-like iPSCs) became similar to TM cells in both morphology and expression patterns. When transplanted, they were able to fully restore intraocular pressure homeostatic function. This successful transplantation of TM-like iPSCs establishes the conceptual feasibility of using autologous stem cells to restore intraocular pressure regulatory function in open-angle glaucoma patients, providing a novel alternative treatment option. STEM CELLS 2015;33:751-761

show abstract

“…Many studies31–37 have evaluated compliance with glaucoma medications, which consistently report, much like in other therapeutic areas, that compliance decreases as regimens become more complicated. Patients may decide that their adjunctive therapies are not important enough to use regularly and physicians may not realize that patients are not using them as prescribed.…”

Section: Discussionmentioning

confidence: 99%

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs

Schmier

Hulme-Lowe

Covert

2014

OPTH

View full text Add to dashboard Cite

PurposeTo analyze patterns of use of adjunctive therapies among new initiators of topical prostaglandin analogs (PGAs) in a managed care population.MethodsThe study cohort included patients in a claims database who initiated PGA therapy between June 2007 and April 2011. Patients who had one or more adjunctive therapy prescriptions during 24 months of follow-up were included. Patterns of adjunctive therapy use were identified and compared between patients who had one or two fills of the initial adjunctive therapy and those who had three or more.ResultsThere were 16,486 eligible beneficiaries. Of these, 5,933 (36%) had one or more adjunctive therapies within 24 months from the start of the PGA, 82% of whom started adjunctive therapy within 12 months. About 28% of patients started adjunctive therapy with a fixed-combination product; 45% of these patients started within the first 30 days. Overall, a large number of patients (42%) required adjunctive therapy within 30 days. Twenty-five percent of patients had only one or two prescriptions of their initial adjunctive therapy; of these patients, 74% discontinued adjunctive therapy altogether.ConclusionApproximately 30% of patients starting glaucoma therapy will require adjunctive therapy within 1 year, and many receive a fixed-combination product as initial adjunctive therapy shortly after starting glaucoma therapy. This suggests a prescribing trend toward earlier, more aggressive drug therapy to control pressure and minimize disease progression. We found that compliance with adjunctive therapy continues to be a problem for patients, which could be attributed to a number of treatment burden and economic factors.

show abstract

Compliance and adherence in glaucoma management

Cited by 104 publications

References 22 publications

Drug use in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital

Drug use in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital

Induced Pluripotent Stem Cells Restore Function in a Human Cell Loss Model of Open-Angle Glaucoma

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs

Contact Info

Product

Resources

About